Short-acting Beta Agonists Market - Top Companies and Manufacturers

Companies Dominating the Short-acting Beta Agonists Landscape

Bayer AG

Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis

Teva Pharmaceutical Industries Ltd.
Viatris Inc.
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc.
Cipla Inc.
Merck & Co., Inc.
Schering-Plough Corporation
AstraZeneca
Johnson & Johnson Services, Inc.

Browse Key Market Insights with Data Illustration:

Short-acting Beta Agonists Market Size & Share, Forecast Report 2036

In the News

FDA approved Airsupra inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients 18 years and older. It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved in the U.S. and the first product containing an ICS to be approved in the U.S. as a reliever treatment for asthma.
Bayer has acquired Blackford Analysis Ltd, a global imaging AI platform and solutions provider. Blackford's clinical application ecosystem for imaging and analytics is now a wholly-owned subsidiary of Bayer, but Blackford will continue to operate independently.

Frequently Asked Questions (FAQ)

The rising prevalence of respiratory disorders and diagnosis rate, increasing investments in research and development activities, and rising patient-centric approaches are some of the major drivers for the Short-acting Beta-Agonists Market.

The market size of Short-acting Beta Agonists is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.

The major players in the market are Teva Pharmaceutical Industries Ltd., Viatris Inc., F.Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Cipla Inc., Merck & Co., Inc., Schering-Plough Corporation, AstraZeneca, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited and others.

The Solutions segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Short-acting Beta Agonists Market - Top Companies and Manufacturers

Companies Dominating the Short-acting Beta Agonists Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the short-acting beta agonists market?

What would be the CAGR of the short-acting beta agonists market over the forecast period?

Who are the major players dominating the short-acting beta agonists market?

Which segment captures the largest market size in the Dosage Form segment in the short-acting beta agonists market?

Which region will provide more business opportunities for the growth of the short-acting beta agonists market in the future?